This application proposes continued funding of the Harvard University Center for AIDS Research (HU CFAR). HU CFAR represents each of the Harvard affiliated schools and hospitals, including Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Children's Hospital Boston, the Immune Disease Institute, Massachusetts General Hospital, Brigham &Women's Hospital, Lemuel Shattuck Hospital, and the New England Primate Research Center. HU CFAR's goals are: 1) to consolidate and expand existing collaborations among the diverse and highly successful HU-affiliated HIV/AIDS researchers, 2) to promote new interactions and innovative research initiatives capable of more effectively addressing key AIDS research questions and 3) to attract and support the next generation of young scientists into HIV research. HU CFAR builds collaborations and provides infrastructure support to coordinate and address emerging research opportunities in basic, clinical, behavioral, and translational AIDS activities. Research emphasis among investigators includes studies of molecular virology, pathogenesis, host immune responses, epidemiology, treatment, vaccines and prevention. CFAR funding will provide administrative resources to address the most significant scientific questions in AIDS in six identified Scientific Programs: Behavioral and Social Sciences, Clinical Epidemiology and Outcomes Research, International, Pathogenesis, Therapeutics, and Vaccines. Five Core facilities have also been identified for continued HU CFAR support: Clinical, Molecular Virology/Genomics, Immunology, Biostatistics, and Small Animal Containment. In addition, the Administrative Core will provide strategic planning and fiscal oversight;the Developmental Core will support innovative pilot projects related to the goals of the scientific programs. HU CFAR will continue to expand, promote, and facilitate collaborative, multidisciplinary activities in AIDS research among CFAR members as the Harvard University model for collaborative inter-institutional interactions. Future planned activities include the development of junior investigators, expansion of the Behavioral and Social Sciences Program, development of the Molecular Virology/Genomics Core facilities, expansion of access to international clinical specimens, expansion of international research and educational activities, community outreach activities and further collaborations with other CFARs.

Public Health Relevance

The HU CFAR is a comprehensive Center providing the infrastructure to integrate Harvard University's multidisciplinary AIDS-related clinical and basic research programs. This provides a unique platform to maximize the contribution to public health by Harvard's HIV/AIDS investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI060354-08
Application #
8125043
Study Section
Special Emphasis Panel (ZAI1-SV-A (J3))
Program Officer
Namkung, Ann S
Project Start
2004-07-01
Project End
2014-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
8
Fiscal Year
2011
Total Cost
$4,620,425
Indirect Cost
Name
Harvard University
Department
Type
Organized Research Units
DUNS #
082359691
City
Cambridge
State
MA
Country
United States
Zip Code
02138
O'Cleirigh, Conall; Pantalone, David W; Batchelder, Abigail W et al. (2018) Co-occurring psychosocial problems predict HIV status and increased health care costs and utilization among sexual minority men. J Behav Med 41:450-457
Mitton, Julian A; North, Crystal M; Muyanja, Daniel et al. (2018) Smoking cessation after engagement in HIV care in rural Uganda. AIDS Care 30:1622-1629
Thomas, Beena E; Subbaraman, Ramnath; Sellappan, Senthil et al. (2018) Pretreatment loss to follow-up of tuberculosis patients in Chennai, India: a cohort study with implications for health systems strengthening. BMC Infect Dis 18:142
Castillo-Mancilla, Jose R; Morrow, Mary; Boum, Yap et al. (2018) Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. J Acquir Immune Defic Syndr 77:507-513
Mayer, Kenneth H (2018) Old Pathogen, New Challenges: A Narrative Review of the Multilevel Drivers of Syphilis Increasing in American Men Who Have Sex With Men. Sex Transm Dis 45:S38-S41
Cheng, Hao D; Grimm, Sebastian K; Gilman, Morgan Sa et al. (2018) Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight 3:
Kirtane, Ameya R; Abouzid, Omar; Minahan, Daniel et al. (2018) Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. Nat Commun 9:2
Mayer, Kenneth H; Chan, Philip A; R Patel, Rupa et al. (2018) Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States. J Acquir Immune Defic Syndr 77:119-127
Calabrese, Sarah K; Earnshaw, Valerie A; Krakower, Douglas S et al. (2018) A Closer Look at Racism and Heterosexism in Medical Students' Clinical Decision-Making Related to HIV Pre-Exposure Prophylaxis (PrEP): Implications for PrEP Education. AIDS Behav 22:1122-1138
Richterman, Aaron; Cheung, Hoi Ching; Meiselbach, Mark K et al. (2018) Risk Factors for Self-Reported Cholera Within HIV-Affected Households in Rural Haiti. Open Forum Infect Dis 5:ofy127

Showing the most recent 10 out of 1030 publications